Axsome Q1 2023: Auvelity sales $15.7M, total revenue $94.6M, net loss narrows to $11.2M

Axsome Therapeutics, Inc.

2023-Q1 EPS reported -$0.26 revenue$94,576,000

Auvelity net product sales $15.7M in first full quarter; ~31,000 prescriptions, up 298% vs Q4 2022.
Total Q1 revenue $94.6M including $65.7M upfront from Sunosi ex-U.S. license to Pharmanovia; net loss $(11.2)M ($0.26/sh) vs $(39.6)M ($1.03/sh) a year ago.
Sunosi net sales $12.9M (U.S. $11.2M, int'l $1.7M); U.S. prescriptions up 13% YoY and 4% sequentially.
Amended Hercules term loan to $350M with reduced rate, extended maturity; cash $246.5M at March 31.
Pipeline milestones: AXS-12 Phase 3 narcolepsy topline Q2 2023; AXS-07 migraine NDA resubmission 2H 2023; AXS-14 fibromyalgia NDA submission Q4 2023.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Axsome Therapeutics, Inc. reported the first quarter ended March 31, 2023 results: revenue $94.6 million, net income net loss of $11.2 million, EPS $(0.26) per share.

Period: the first quarter ended March 31, 2023
Revenue: $94.6 million
Net income: net loss of $11.2 million
EPS: $(0.26) per share
Result: reported results

Exact text from the filing

2023 Financial Results and Corporate Update Auvelity ® 1Q 2023 net product sales of $15.7 million Total 1Q 2023 net product sales of $28.6 million Total 1Q 2023 revenue of $94.6 million, including Sunosi ® ex-U.S. license agreement upfront payment Company to host conference call today at 8:00 AM Eastern NEW YORK, May 8, 2023 (GLOBE NEWSWIRE) -- Axsome

View on SEC.gov

Browse all earnings releases →

Axsome Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-23-018467

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.